June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Abner Antonio Murray: KRYSTAL-7 Trial at ASCO25
Jun 2, 2025, 09:06

Abner Antonio Murray: KRYSTAL-7 Trial at ASCO25

Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, posted on X:

KRYSTAL-7 | ASCO25

First-line adagrasib (ADA) + pembrolizumab (PEMBRO) brings a chemo-free option to the frontline for KRASG12C-mutant NSCLC!

Presented by Dr. Pasi Jänne (Dana-Farber)
Oral Abstract 8500 | ASCO LCSM

Key results (n = 149):

  • ORR: 44%
  • DCR: 81%
  • mPFS: 11.0 months
  • mDOR: 26.3 months (12-month DOR rate = 73%)
  • mOS: Not reached in PD-L1 ≥50%

PD-L1 subgroup OS:

  • TPS ≥50% → Not Reached
  • TPS 1–49% → 14.3 months
  • TPS <1% → 15.5 months

Safety:

  • Grade ≥3 TRAEs in 58%
  •  Most common: nausea (56%), diarrhea (47%), ALT increase (40%)
  • Immune AEs: pneumonitis (12%), hypothyroidism (7%)
  • Hepatic TRAEs in 59%, mostly mild/moderate

Takeaways:

  • Durable responses in first-line setting
  • Benefit enriched in PD-L1 ≥50%
  • ADA + PEMBRO shows real potential as a chemo-sparing regimen
  • Escalation (e.g., adding chemotherapy) may be needed for lower PD-L1 expression

Now enrolling phase 3:

  • KRYSTAL-7 (ADA + PEMBRO vs PEMBRO)
  • KRYSTAL-4 (ADA + PEMBRO + chemotherapy).”

Abner Antonio Murray: KRYSTAL-7 Trial at ASCO25

More posts featuring ASCO25.